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ARTICLE OPEN
Sustained release of decorin to the surface of the eye enables
scarless corneal regeneration
Lisa J. Hill1, Richard J. A. Moakes2, Chairut Vareechon3, Gibran Butt4,5, Aaron Ng4,5, Kristian Brock6, Gurpreet Chouhan2,
Rachel C. Vincent4, Serena Abbondante3, Richard L. Williams2, Nicholas M. Barnes1, Eric Pearlman3, Graham R. Wallace4, Saaeha Rauz4,5,
Ann Logan4 and Liam M. Grover2
Disorganization of the transparent collagenous matrix in the cornea, as a consequence of a variety of infections and inﬂammatory
conditions, leads to corneal opacity and sight-loss. Such corneal opacities are a leading cause of blindness, according to the WHO.
Public health programs target prevention of corneal scarring, but the only curative treatment of established scarring is through
transplantation. Although attempts to minimize corneal scarring through aggressive control of infection and inﬂammation are
made, there has been little progress in the development of anti-scarring therapies. This is owing to eye drop formulations using low
viscosity or weak gelling materials having short retention times on the ocular surface. In this study, we report an innovative eye
drop formulation that has the ability to provide sustained delivery of decorin, an anti-scarring agent. The novelty of this eye drop
lies in the method of structuring during manufacture, which creates a material that can transition between solid and liquid states,
allowing retention in a dynamic environment being slowly removed through blinking. In a murine model of Pseudomonas keratitis,
applying the eye drop resulted in reductions of corneal opacity within 16 days. More remarkably, the addition of hrDecorin resulted
in restoration of corneal epithelial integrity with minimal stromal opacity endorsed by reduced α-smooth muscle actin (αSMA),
ﬁbronectin, and laminin levels. We believe that this drug delivery system is an ideal non-invasive anti-ﬁbrotic treatment for patients
with microbial keratitis, potentially without recourse to surgery, saving the sight of many in the developing world, where corneal
transplantation may not be available.
npj Regenerative Medicine            (2018) 3:23 ; https://doi.org/10.1038/s41536-018-0061-4
INTRODUCTION
Corneal opacity is a leading cause of sight impairment worldwide
with an estimated 27.9 million people globally being bilaterally or
unilaterally affected.1 Such opacity is typically derived from
alteration of the complex, optically clear, corneal tissue structure,
vital for refraction of light onto the retina, and subsequent neuro-
visual processing. Commonly, corneal scarring results from ocular
infections from a range of pathogens, including bacteria, parasites,
fungi, viruses, and protozoa. In the developed world, devastating
corneal infections are most commonly associated with prolonged
contact lens wear and/or poor lens hygiene,2–4 with Pseudomonas
aeruginosa being a prominent causative organism. In cases of
gram-negative infections, e.g., Pseudomonas, the structural integ-
rity of the cornea becomes compromised through multiple
virulence factors, whereby the microbes invade epithelial cells,
resulting in activation of numerous inﬂammatory pathways.
Subsequent production of cytokines from epithelial, stromal and
intraepithelial inﬂammatory cells, neovascularization, cellular
alterations and degradative stromal processes5 lead to dysregu-
lated tissue remodeling and disruption of the intricately arranged
collagen ﬁbrils,6 leading to the loss of optical transparency,
impairment of light refraction and loss of sight.
Following injury that breaches the epithelium and Bowman’s
layer involving the corneal stroma, an orchestrated wound healing
response involving corneal epithelium, stroma and nerves,
lacrimal glands and tear ﬁlm occurs to restore corneal structure
and function and maintain the ocular integrity.7 As part of the
corneal wound healing response, the epithelium starts to
regenerate in response to stem cell proliferation from the limbal
niche almost immediately after the epithelium is injured8 and
keratocytes (transparent cells that function to maintain collagen
and extracellular matrix (ECM) turnover) proximal to the wounding
site undergo apoptosis (induced by cytokines released from
damaged epithelial cells). Proliferation and migration of residual
keratocytes peripheral to the injury-site can be detected 12 to 24 h
after injury.9 The keratocytic response includes production of
proteoglycans and synthesis of collagen ﬁbers. These ﬁbers are
larger than those in an uninjured cornea and, owing to the water-
retention capacity of the proteoglycans, do not assume an
ordered regular architecture leading to corneal opacity. The
movement of bone marrow-derived precursor cells and circulatory
mediators from the limbal region activate, transform, and
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differentiate a subset of keratocytes to cell types with ﬁbroblast
and myoﬁbroblast characteristics via Transforming Growth Factor
(TGF)β and platelet-derived growth factor (PDGF) activation.9–11
TGFβ released from epithelial cells access stromal cells through
the damaged Bowman’s layer to initiate myoﬁbroblast differentia-
tion.12,13 Myoﬁbroblasts release cytokines that further attract
inﬂammatory cells and ECM deposition (e.g., collagen, ﬁbronectin)
to facilitate the ﬁbroblast migration as part of the stromal
remodeling phase.14 Reparative processes lead to collagen ﬁber
orientation closer to that in the uninjured cornea, contraction of
proteoglycan, apoptosis of the stromal myoﬁbroblasts, and re-
population of keratocytes enable structural and functional
recovery, but with residual stromal opacity. If this is present in
the visual axis, sight is impaired. If the corneal epithelial barrier is
not restored, stromal metabolism becomes dysregulated leading
to keratolysis, degradation of corneal tissue, further disorganiza-
tion of corneal ﬁbril arrangements, and eventual corneal perfora-
tion. This is partly due to the sustained release of TGFβ leading to
persistent myoﬁbroblasts preventing stromal re-population of
keratocytes.15,16 Unlike other tissues (e.g., skin), where a persistent
ulcer or scar might be tolerated, in the cornea this can have
devastating functional effects of permanent corneal scarring with
visual disability or loss of eye.
At present, the standard of clinical care for patients infected
with bacterial keratitis focuses initially on sterilizing the infected
eye, by eye drop administration of intensive broad-spectrum
antibiotics, followed by the addition of topical corticosteroids to
reduce inﬂammation.17,18 This is followed by strategies to limit
scar formation ranging from intensive lubrication (to reduce
biomechanical trauma of the eyelids abrading the wound bed
during blinking), to the use of systemic pharmacological agents
(sub-antimicrobial dose of tetracyclines for matrix metalloprotei-
nase inhibition19) or supplements (vitamin C used as antioxidants
and free-radical scavengers20) in an attempt to promote tissue
remodeling. Unfortunately, although effective at sterilizing the
eye, the patient is often left with a high degree of corneal hazing
and astigmatism which, if it compromises the visual axis, causes
loss of visual acuity. Surgical interventions to treat unresponsive
and large corneal defects include either application of amniotic
membrane as a biologically active bandage releasing anti-
inﬂammatory and anti-ﬁbrotic factors to enhance re-
epithelialization and wound healing during acute injury,21–23 or
in established cases of visually signiﬁcant central corneal scars,
excision of the scarred tissue, and replacement with donor cornea.
Reproducibility and repeatability of the clinical outcomes of
amnion grafting and corneal transplantation are low and fraught
with risks of failure and rejection.24–27 Enhancement of re-
epithelialization, prevention of keratolysis, and minimization of
ﬁbrosis are pivotal to effective wound healing, mitigating the need
for surgical intervention and transplantation. An innovation that
could saturate TGFβ activity28–30 and provide an exogenously
placed barrier to enable a microenvironment that minimizes
corneal damage following the injury response, could have the
potential to prevent permanent sight-loss in many millions of
individuals worldwide.
Decorin is a naturally occurring, pleiotropic, small leucine-rich
proteoglycan that is naturally present at high levels bound to
collagen in the corneal stroma and which, when released, tightly
regulates TGFβ activity by binding the growth factor and
sequestering it within the ECM.31 Decorin regulates cell prolifera-
tion, survival, and differentiation by modulating numerous growth
factors,32–35 including TGFβ as well as directly interfering with
collagen ﬁbrillogenesis.36–39 Decorin is responsible for regulating
collagen ﬁbril spacing and ECM to enable corneal transparency
and has previously been shown to inhibit scar formation and
neovascularization in the cornea.35 Mutations in decorin are
associated with corneal opacities and visual abnormalities
associated with congenital stromal dystrophy.40 Hyperactivity of
TGFβ in corneal ﬁbrosis may overcome the ability of endogenous
decorin to maintain homeostasis and there is good evidence that
overexpressing decorin in other tissues is able to reduce levels of
ﬁbrosis in vivo.41–43
Human recombinant (hr)Decorin is now available in GMP form
and this same molecule has been shown to minimize ﬁbrosis in
other in vivo models of brain and spinal cord injury.44–46 To date,
there has been no reported efﬁcacy of soluble decorin being
applied to the surface of the eye for treatment in vivo. One of the
possible reasons for this maybe the relatively rapid clearance of
eye drops (in the range of minutes47,48), owing to their relatively
low viscosities, from the surface of the cornea at early time points,
meaning that any efﬁcacy of decorin would be limited. In this
paper, we report a new class of eye drop material that allows for
prolonged retention of a therapeutic on the surface of the eye,
while being gradually cleared through the blinking process. The
material is formed through the shearing of a gellan-based
hydrogel, a material that is currently used in dilute form to
thicken eye drops (e.g., Timoptol) during the gelation process. The
application of shear prevents the formation of a continuous
polymeric network and results in the formation of interacting
particles that can exhibit spherical and ribbon-like morphology.
Following shear-processing, these particles interact and form a
continuous structure when the solution is at rest. When shear is
applied (such as when extruded through an eye dropper),
however, the continuous network of particles is disturbed and
the material liqueﬁes. Subsequent removal of the shear force
results in an immediate healing. The solid–liquid–solid transitions
that this material is able to undergo means that it conforms
perfectly to the ocular surface and is removed gradually by the
eyelid-blinking dynamics. Importantly, gellan gum is optically
transparent and so the material can continue to transmit light
following application, causing minimal disruption to the patient.
We have developed a ﬂuid gel eye drop, which can be loaded
with decorin, to provide localized drug delivery and retention at
the surface of the eye. The material combines structured gellan
gum with the proteoglycan, decorin. Additionally, in conjunction
to high optical clarity, the FDA approved polymer (FDA reference
number 172.665) coupled with clinical grade hrDecorin, provides a
rapid route to translation into the clinic. As such, this study
investigated the effects of ﬂuid gel, with and without hrDecorin,
on corneal opacity, wound healing and ﬁbrosis within a well-
established murine model of Pseudomonas keratitis, as a precursor
to clinical application for the management of severe bacterial
infection.
RESULTS
Fluid gel formulation and properties
Processing of the ﬂuid gel involves passing a polymer solution,
gellan, through a jacketed pin-stirrer, where it experiences high
levels of shear while being forced (thermally) through its sol–gel
transition (Fig. 1a). This restricts the long-range ordering normally
observed in the formation of quiescent gels, restricting growth of
the gel nuclei to discrete particles.49 The microstructures within
the eye drop prepared in this way have been shown using two
techniques: (1) optical microscopy, whereby the refractive index of
the continuous phase was manipulated using polyethylene glycol,
and (2) lyophilizing in order to image using scanning electron
microscopy (SEM) (Fig. 1a(i) and 1a(ii), respectively). Both
microscopic techniques highlight the stranded microstructure of
the resulting gelled entities, where their large length to width ratio
and subsequent large hydrodynamic radii, give rise to the
resulting material properties (viscosity and elastic structuring).50
The unique properties of ﬂuid gels are such that they exhibit
pseudo-solid properties at rest, but can be made to ﬂow under
force. Here, increasing the shear force exerted on the system
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results in non-Newtonian, shear thinning behavior, typical of
highly ﬂocculated or concentrated polymer dispersions/solu-
tions51 (Fig. 1b). As such, at low shear, large viscosities exceeding
several orders of magnitude higher than typical water-based eye
drops are observed, thinning during application and subsequent
blinking as a result of dis-entanglement and alignment of particles
in ﬂow.52,53 This makes the microgel suspension ideal for
application through dropper bottles, rapidly shear thinning
through the nozzle on application to the eye (Fig. 1c). Post
application, restoration of the three-dimensional structural matrix
is key to gaining high retention times upon the ocular surface.
Time-dependent removal of shear, at comparative timescales to
the initial ramp, was used to gather information regarding such
structuring, probing eye drop hysteresis. The eye drop system
showed a degree of thixotropy (Fig. 1b), whereby the majority of
the original viscosity was recovered. The presence of weak
interactions between gel-ribbons were examined using linear
rheology, with the evolution of an elastic structure at strains
within the linear viscoelastic region (Fig. 1d). It was observed that
initially, post-shear, the ﬂuid gel exhibited typical liquid-like
behavior with the loss modulus (G”) dominating the storage
modulus (G’). Following this, an increase in G’ as a function of the
formation of interactions between gelled ribbons led to a
crossover being reached, at which point the system began to
behave as a solid–gel.54 Further structuring over time thus leads to
pseudo-solid behaviors, where a continuous network is formed
between the gelled entities. The ability to shear-thin on
application, while being able to quickly restructure post shearing,
enables the eye drop to be applied to the ocular surface, acting as
a barrier. Using a single 5 µl application of ﬂuid gel eye drop, it was
demonstrated that a uniform distribution of gel covers the entire
ocular surface including cornea, adjacent conjunctiva and fornices
(space between the eyelid and eyeball) in a rodent eye (Fig. 1e).
In vitro eye drop activity
The gellan-based eye drop system was formulated for drug
delivery with the candidate anti-ﬁbrotic agent, hrDecorin, used for
our studies. The rate of release of hrDecorin from the eye drop
system was almost linear over time (Fig. 2a). Turbidity was used as
a measurement of ﬁbrillogenesis (formation of large, disorientated
collagen ﬁbers), shown as a function of the hrDecorin (Fig. 2b, c). It
was evident that hrDecorin played a key role in the kinetics of ﬁbril
formation, slowing the onset of ﬁbrillogenesis, and also reaching
an equilibrium much faster (Fig. 2b). Above a critical concentra-
tion, 0.5 μg/ml, an active effect of hrDecorin in inhibiting
ﬁbrillogenesis was observed, highlighting a concentration depen-
dency until a minimum turbidity is achieved (> 10 μg/ml), above
Fig. 1 Processing and intrinsic material properties of the gellan-based ﬂuid gel eye drop. a Schematic showing the production of the ﬂuid gel:
where the initial sol is continuously processed under shear whilst being cooled to form “ribbon-like” gelled entities shown using (i)
transmission microscopy and (ii) scanning electron microscopy. b Time-dependent viscosity proﬁles obtained for the gellan eye drop,
highlighting a degree of thixotropy. c The ﬂuid gel being dispensed from the eye dropper packaging (gel has been stained blue so as to be
visible in the photograph). d Small deformation rheology data obtained at a single frequency (1 Hz, 0.5% strain) as a function of time. Data
show the evolution of an elastic network post-shearing resulting in a transition from liquid to solid-like behavior. e Anterior segment OCT
images showing the ocular surface before ﬂuid gel application (top image) and post application (bottom image). Images demonstrate a
uniform layer that covers the entirety of the ocular surface
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which no further reduction occurs (Fig. 2c). Furthermore, the assay
demonstrated that the ﬂuid gel carrier had no effect on ﬁbril
formation, correlating closely with the collagen only controls.
In vivo efﬁcacy of the loaded/unloaded eye drop on corneal
opacity
Using a well-established model of bacterial keratitis,55 anaesthe-
tized mice (n= 6 per group) were challenged with P. aeruginosa
(105 colony-forming unit; CFU) upon the surface of the damaged
cornea. A therapeutic protocol to treat the infection based upon
the standard treatment for bacterial keratitis patients was
developed. After 12 h of P. aeruginosa incubation to establish
the corneal infection, eyes were treated with a 2-hourly regime of
gentamicin (1.5%) over a 12-hour period to sterilize the infection
(conﬁrmed by swab cultures). Following the sterilization phase,
2 days after the initial inoculation, single 5 µl gellan eye drops
were administered every 4 h between 8 am and 8 pm for a further
13 days covering the treatment groups of (1) Gentamicin and
Prednisolone (G.P); (2) Gentamicin, Prednisolone, and ﬂuid gel (G.
P.FG) and; (3) Gentamicin, Prednisolone, and hrDecorin ﬂuid gel
(G.P.DecFG) (Table 1).
No evident systemic toxicity was present in mice after
treatments and no systemic exposure to decorin was detected
from serum (Supp. Figure 1). The ﬂuid gel and hrDecorin ﬂuid gel
were all tested in accordance with ISO10993 biocompatibility
standards, tests were undertaken by an accredited Contract
Research Organisation. Both of the formulations passed with
direct toxicity assessments failing to identify any toxicity
associated with the ﬂuid gel or the hrDecorin ﬂuid gel in the
ISO battery of in vitro and in vivo assays.
Images of the cornea were taken at intervals throughout the 16-
day experiment to measure changes in corneal opacity (Fig. 3a).
All mice were euthanized on day 16. The area of opacity
(measured independently by two clinical ophthalmologists,
masked to treatment groups) showed earlier size-reduction in
eyes treated with the ﬂuid gel and with the hrDecorin ﬂuid gel eye
drops plus standard of care compared with eyes treated with
standard of care (Gentamicin and Prednisolone) treatments alone.
Accordingly, at day 9, eyes treated with the standard of care with
hrDecorin ﬂuid gel, showed signiﬁcantly (p < 0.001) lower opaque
areas (1.9 ± 0.3 mm2) compared with eyes treated with Gentamicin
and Prednisolone only (3.5 ± 0.4 mm2). At 12 days, the mice that
received hrDecorin ﬂuid gel eye drops with standard of care
maintained signiﬁcantly lower (p < 0.01) opaque area compared
with the Gentamicin and Prednisolone group, and also to the ﬂuid
gel group with standard of care (mean opacity area in Group 1=
3.5 ± 0.7 mm2, Group 2= 3.0 ± 0.1 mm2, in comparison to Group 3
= 2.1 ± 0.2 mm2; Fig. 3b).
Effects of the ﬂuid gel eye drops with and without hrDecorin on
corneal re-epithelialization
Epithelial stratiﬁcation/maturation together with stromal thickness
were chosen as outcome measures to assess corneal re-
epithelialization, and to observe thickening of the stroma from
edema and cellular inﬁltrates (as markers of infection). Pseudo-
monas infection severely disrupted the corneal structure, with an
averaged increased corneal thickness of 219 ± 24 µm after the
infection on day 2 compared with naive corneal thickness values
of 129 ± 11 µm. The infected corneas at day 2 had thinner
epithelial layers compared with normal intact controls (19.2 ±
2.1 µm vs 35.5 ± 1.7 µm; Fig. 4a, b). With the addition of ﬂuid gel
alone and with hrDecorin eye drops treatments over 13 days it
was evident that re-epithelialization was improved. Treatment
with the hrDecorin loaded ﬂuid gel eye drop led to an epithelial
layer with an improved degree of stratiﬁcation (26.1 ± 2.4 µm thick
made up of 3.6 ± 0.2 cell layers) compared with the epithelium in
the Gentamicin and Prednisolone group (22.5 ± 2.1 µm thick with
2.7 ± 0.2 cell layers) as well as the Gentamicin, Prednisolone, and
ﬂuid gel group (22.8 ± 1.3 µm thick with 3.4 ± 0.1 cell layers).
However, the differences between the various groups did not
reach statistical signiﬁcance (Fig. 4b, c, d).
Fig. 2 In vitro assays demonstrating the formulated eye drop’s bioactivity. a Cumulative release curve for hrDecorin loaded eye drops over 4 h
(240min). Line of best ﬁt follows a power function, y=0.7x0.7 (R2= 0.99). b Collagen ﬁbrillogenesis turbidity data for PBS control, collagen only
and collagen+ hrDecorin. c Collagen ﬁbrillogenesis turbidity data with a dose response curve for collagen, collagen+ hrDecorin, collagen+
ﬂuid gel (FG) only, collagen+ hrDecorin loaded ﬂuid gel (DecFG)
Table 1. Table of treatment groups
Therapeutic
Group no. Gentamicin Prednisolone Fluid gel (FG) hrDecorin+
Fluid gel
(DecFG)
1 + + − −
2 + + + −
3 + + − +
Table highlighting the combination of therapeutics administered (+) or
not administered (−) to each group, n= 6.
L.J. Hill et al.
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Effects of the ﬂuid gel on levels of myoﬁbroblasts and extracellular
matrix
Immunoreactivity (IR) was used to assess the degree of ﬁbrosis, as
a ratio of pixel intensity above a baseline obtained from intact
corneas (referred to here on as the threshold). In the naive intact
cornea, there were very low levels of α-smooth muscle actin
(αSMA) IR in the corneal stroma, indicating the presence of few
myoﬁbroblasts (Fig. 5a). Two days after the infection, 1 day after
sterilization, infected cornea demonstrated a 23% increase in
stromal αSMA staining to levels of 26.5 ± 3.0% above the threshold
(normalized from an intact cornea), indicating increased differ-
entiation of myoﬁbroblasts. Levels of stromal IR αSMA remained
elevated at day 16, at 32.7 ± 6.1% in eyes treated with standard of
care only. When eyes were also treated with the ﬂuid gel eye
drops, either with or without hrDecorin, the level of stromal αSMA
IR was signiﬁcantly lower at day 16, 13.4 ± 2.9% and 2.0 ± 0.4%,
respectively, suggesting less myoﬁbroblast activation within the
corneal stroma. The hrDecorin ﬂuid gel was most effective at
keeping the αSMA IR levels low, resulting in similar values to the
intact cornea, suggesting that the addition of hrDecorin in the
ﬂuid gel had an added beneﬁcial effect on myoﬁbroblast
differentiation versus the ﬂuid gel alone (Fig. 5a).
Stromal ECM levels generated by the myoﬁbroblasts were
studied using ﬁbronectin and laminin IR (Fig. 5b, c). Increased
amounts of stromal IR ﬁbronectin were observed post infection at
day 2, remaining high at day 16 after Gentamicin and
Prednisolone treatment (IR Fibronectin 83.9 ± 5.5% and 75.3 ±
11.5%, at day 0 and 16, respectively). Fluid gel with or without
hrDecorin, signiﬁcantly lowered levels of ﬁbronectin IR to 31.6 ±
5.8% and 13.9 ± 5.3%, respectively, demonstrating borderline
signiﬁcant differences (p= 0.051) between the two eye drop
treatment groups. Levels of IR laminin (Fig. 5c) demonstrated that
the infection increased levels of laminin when compared with the
intact cornea, from 2.15 ± 0.6% in the intact to 16.3 ± 4.6% in the
infection group at day 2. Levels of IR laminin continued to rise by
day 16 after Gentamicin and Prednisolone treatment to 42.5 ±
8.2%. Similar to the Gentamicin and Prednisolone group, average
levels of IR laminin remained high on day 16 after treatment with
the ﬂuid gel, with IR laminin levels at 38.0 ± 12.0%. The addition of
hrDecorin to the ﬂuid gel signiﬁcantly lowered laminin levels
compared with Gentamicin and Prednisolone treatment, (12.4 ±
5.5% vs 42.3 ± 8.2%), whereas the ﬂuid gel without hrDecorin had
no effect on this ECM parameter.
DISCUSSION
Improving ocular retention is key to increasing both bio-efﬁciency
and therapeutic response to topical therapies, as turnover of the
Fig. 3 Corneal opacity area measurements. a Representative photographs taken at days 2, 3, 9, 12, and 16 post Pseudomonas infection and
treatment. b Graph to show the mean area ± SEM (mm2) of opacity as measured by two independent masked ophthalmologists from
photographs (represented in a) taken from each individual mouse per group (n= 6; **p < 0.01, ***p < 0.001)
L.J. Hill et al.
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Fig. 4 Corneal re-epithelialization. a Representative images of DAPI+ cell nuclei (blue) in the cornea used to assess the epithelium, illustrating
the thickness and stratiﬁcation (number of cell layers) of the epithelium in: naive intact eyes showing normal non-keratinized stratiﬁed
(approximately ﬁve layers) epithelium; eyes taken at day 2 after infection, which was associated with a thickened edematous stroma with
cellular inﬁltrate; and eyes taken at 16 days post treatment showing re-epithelization with a 2–3 layer stratiﬁcation accompanied by a
reduction in the stromal edemas in Group 1 (Gentamicin and Prednisolone), increased stratiﬁcation in Group 2 (G.P.FG) and, fully mature
epithelium in Group 3 (G.P.DecFG) (scale bar 100 µm). b Quantiﬁcation of corneal thickness ± SEM. c Quantiﬁcation of epithelial layer thickness
± SEM, and d Quantiﬁcation of cellular epithelial stratiﬁcation layers ± SEM in naive intact, (n= 6), with eyes evaluated at day 2, and at day 16
from each treatment group (n= 6 for each group). All quantiﬁcation was performed on masked images unknown to the observer
L.J. Hill et al.
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pre-corneal tear ﬁlm (ca. 20% per minute56) results in rapid
elimination of aqueous drugs, reducing titers delivered to the
target tissue site. As such, many ocular conditions are currently
treated via intensive topical therapies delivered through the day
and night, or invasive methods disliked by many patients,
including periocular or intravitreal injections to target intraocular
pathology. In more severe cases where drugs are ineffective,
surgery may be required to treat or remove the resultant corneal
scar, increasing the risk of morbidity and increasing the duration
of patient discomfort following treatment. The structured or “ﬂuid
gel” formed from gellan provides a pivotal advance since it
enables the sustained delivery of molecules such as hrDecorin
capable of preventing scarring and obviating the need for invasive
surgical repair strategies. The major advantage of the gellan ﬂuid
gel is its capacity to transition between solid and liquid states as it
passes through the applicator and solidiﬁes on the surface of the
cornea. This unique set of properties originates from the
microstructure of the material, which consisted of ribbons and
particles that weakly interact with one another at zero shear.
These interactions are broken by the application of shear and
reform following its removal. In this way, the material may then be
gradually cleared from the ocular surface through the natural
blinking mechanism. The development of a weak-elastic structure
when applied to the surface of the cornea, results in the formation
Fig. 5 Extracellular matrix levels in the cornea. Representative images of immunohistochemical staining with accompanying plots quantifying
the IR for: a αSMA+ (green to stain myoﬁbroblasts), b IR ﬁbronectin+ (green to stain ﬁbronectin in the ECM), and c laminin+ (red to stain
laminin in the ECM), in each case DAPI+ was used to stain the cell nuclei (blue). Analysis was undertaken on intact eyes, eyes taken at 2 days
post infection and eyes obtained after 16 days with various eye drop treatments: (i) Gentamicin and Prednisolone (G.P), (ii) Gentamicin,
Prednisolone, and ﬂuid gel (G.P.FG), and (iii) Gentamicin, Prednisolone and hrDecorin ﬂuid gel (G.P.DecFG). All studies were done using n= 6
treatment groups, with quantiﬁcation performed on masked images unknown to the observer (scale bar= 100 µm)
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of a transparent and resorbable bandage, with the beneﬁts of eye
drops (in application) and hydrogel lens (sustained release),
without the drawbacks of either. Indeed, the ﬂuid gel alone seems
to provide a m"icroenvironment conducive to wound healing,
with a reduction in corneal opacity and markers of scar formation
even without decorin addition. Importantly, the ﬂuid gel does not
interfere with hrDecorin’s biological activity, as shown by the
collagen ﬁbrillogenesis data. As such, the system provides an
excellent candidate technology for the clinical setting, with
improved drug administration compliance across numerous
patient cohorts.
The mouse model of P. aeruginosa keratitis provides a robust,
clinically relevant means of evaluating the anti-scarring capacity of
the hrDecorin loaded ﬂuid gel against the current standard of care
for Pseudomonas infection (Gentamicin and Prednisolone).57
Topical administration of the ﬂuid gel eye drops either with or
without the hrDecorin resulted in reduced levels of corneal
opacity after 7 and 10 days of eye drop treatments, with the
addition of hrDecorin displaying an evident further advantage
from earlier time points. The effects of the ﬂuid gel only treatment
were not expected as the initial in vitro studies demonstrated that
this carrier appeared inert. The therapeutic efﬁcacy of ﬂuid gel
alone may be due to the formation of a permissive microenviron-
ment in the damaged cornea, where the occlusive effect of the gel
ribbons (that entwine to form a barrier around the wound)
provided a therapeutic bandage that prevented biomechanical
trauma caused by blinking over the ulcerated eye. It may also have
sequestered Prednisolone and Gentamicin within its structure,
enhancing retention of the therapeutic substances to the ocular
surface, thereby improving bioavailability similar to the prosthetic
replacement of the ecosystem (PROSE(TM) device) but with the
added advantage of being resorbable. Such reductions in corneal
opacity would beneﬁt patients in terms of preservation of sight.58
An important aspect to the healing phase encompasses
restoration of a stratiﬁed non-keratinized epithelium. Together
with the tear ﬁlm, an apical mucosa (composed of lipid, mucins
and aqueous layers) provides nutrition and lubrication to the
ocular surface and is fundamental to ﬁrst-line of defense to the
eye. hrDecorin treated eyes exhibited the most improved
restoration to normal anatomy, with a reduction in stromal
edema, thickness and extracellular matrix deposition, coupled
with improved epithelial morphology. The reduction in ﬁbrotic
markers by hrDecorin has been previously demonstrated across
numerous animal models; modulating a range of growth factors
(e.g., VEGF, IGF-1, EGF, PDGF) and their receptors, in particular
TGFβ signaling via SMAD 2 and 3 pathways, preventing
differentiation of corneal ﬁbroblasts. In addition, its regulation of
matrix metalloproteinase and tissue inhibitors of metalloprotei-
nase results in ﬁbrolysis and attenuated scar formation.44,59–61
The intrinsic ability of hrDecorin to aid healing, and in particular
reduce scarring, has been enhanced by introducing the ﬂuid gel
carrier, improving retention time on the ocular surface. Given the
severe extent of injury in this mouse model, we suggest that the
endogenous levels of decorin may not have been sufﬁcient to
neutralize the TGFβ hyperactivity and subsequent ﬁbrotic cascade
to prevent corneal scarring. It is also possible that the endogenous
decorin, located at the ocular surface within the tear ﬁlm, within
the cornea and the aqueous humor, is bound and not freely
available to sequester the active TGFβ (Fig. 6).
A unique feature of both our formulations, i.e., the ﬂuid gel eye
drop and the hrDecorin ﬂuid gel eye drop, was their ability to
enhance the rate of re-epithelialization compared with standard
care. This is central to the limitation of ocular damage as persistent
epithelial defects lead to dysfunctional corneal metabolism,
stromal melts, and perforation. The addition of hrDecorin in the
ﬂuid gel eye drop formulation reduced ECM accumulation more
than the standard of care and the ﬂuid gel alone and, this was
associated with further reductions in opacity (compared with
earlier time points) in this model. This suggests our hrDecorin ﬂuid
gel eye drop provided sufﬁcient doses to prevent ﬁbrosis and
promote wound resolution in this model or altered the chemical
structure of the ﬂuid gel to improve the bandaging effect. The
beneﬁts of this ﬂuid gel formulation have been clearly demon-
strated in vivo, observed both physically, with a reduction in
corneal opacity, and pharmacologically, relating to diminished
ﬁbrotic markers. However, owing to legislative constraints, the
data generated within this study was limited to a 16 day time
point and it would be of interest to examine later time points in
future studies.
The effects of the ﬂuid gel alone on the damaged corneal
surface suggest an inﬂuence over the endogenous growth factors,
an effect that is enhanced by the addition of hrDecorin. The ﬂuid
gel may aid corneal healing through several mechanisms: ﬁrst, the
unique viscoelastic properties of the ﬂuid gel acts as a liquid that
self-structures upon the ocular surface to form a semi-solid
occlusive therapeutic dressing for unperturbed healing to take
place; second, helical domains formed during the gelation of the
ﬂuid gel may provide a mimetic scaffold for endogenous decorin
to bind, sequestering key growth factors, e.g., TGFβ and/or
exogenously delivered hrDecorin; third, the ﬂuid gel matrix,
comprising primarily of water (99.1%), creates a gradient driven
diffusion of cytokines away from the wound site, again resulting in
a restoration of the natural equilibrium needed to prevent ﬁbrosis.
We have seen two different responses in the presence of the
ﬂuid gel and the Decorin ﬂuid gel, and in future studies, it will be
important to tease apart the mechanism for each. We expect that
the ﬂuid gel alone is providing a protective barrier while
potentially inﬂuencing inﬂammatory cell and ﬁbroblast behavior
in a manner that we do not yet understand. Importantly, the ﬂuid
gels are facilitating regeneration of the corneal epithelium leading
to wound closure. We are hypothesizing that the ﬂuid gel is
affecting the limbal epithelium stem cell niche by promoting
proliferation and differentiation, which may be dysregulated in the
disease situation as well as providing a therapeutic bandage to aid
stromal repair. However, in this study we did not have a
hyaluronate or a carboxymethylcellulose only group to interrogate
whether these ocular lubricant devices have a similar effect.
Furthermore, the multifaceted actions of decorin such as
inhibition of inﬂammation and angiogenesis and regulation of
autophagy, in addition to sequestering TGFβ within the context of
an ocular wound healing environment, need to be investigated
further before translation into the clinic.
In conclusion, we have demonstrated that a novel eye drop
technology can be used to provide sustained delivery of anti-
ﬁbrotic drugs like hrDecorin topically to the cornea in a clinically
relevant murine model of ﬁbrosis associated with bacterial
keratitis. The eye drop enabled the hrDecorin to remain in contact
with the surface of the eye for long enough and at sufﬁcient titers
to signiﬁcantly reduce corneal scarring or altered the structure of
the gel to provide better therapeutic bandaging. Furthermore, this
study has demonstrated that the unloaded ﬂuid gel also possesses
healing effects in its own right, suggested to arise through its
intrinsic material microstructure and subsequent properties. Not
only do the material properties of the eye drop enhance anti-
scarring drug retention times, but the user-friendly nature of the
drops would be welcomed by patients, providing a simple
treatment to prevent the scarring pathology that is prevalent
after corneal infection. Having demonstrated successful reduction
in corneal opacity and a reduction in markers commonly
indicative of the scarring process, when compared with the
current standard of care, this technology presents an ideal
treatment option for patients with microbial keratitis, reducing
the occurrence of visually signiﬁcant corneal opacity and
potentially eradicating the need for corrective surgical interven-
tion. Given that transplant availability and the facilities for surgical
intervention are often not available in the developing world, we
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believe that this technology could, in the future, help to save the
sight of many patients.
MATERIALS AND METHODS
Study design
All studies were approved by the Universities of Birmingham, UK, and
California, Irvine with all mouse studies maintained according to the
ARRIVE guidelines and in accordance with the ARVO statement for the Use
of Animals in Ophthalmic and Vision Research. The aim of this study was to
explore the use of a novel ﬂuid gel to deliver hrDecorin to the ocular
surface in order to reduce corneal opacity and scarring post-bacterial
keratitis. The study was split into three evaluation stages: (i) material
properties relating to ease of eye drop application, (ii) in vitro assessment
of bioactivity of the formulated hrDecorin, and (iii) anti-scarring efﬁcacy of
the ﬂuid gel with/without hrDecorin in vivo, using a mouse model of
Pseudomonas keratitis (once the eyes were sterilized after infection) in
comparison with the current standard of care. The sample size (n= 6 per
experimental group) was based on the resource equation as the effect size
was unknown. All analyses were performed by observers masked to
experimental groupings and mice were randomly assigned to both
treatment and control groups.
Fluid gel (FG) and hrDecorin ﬂuid gel (DecFG) production
Preparation of ﬂuid gel eye drops: Fluid gels were produced by ﬁrst
dissolving low acyl gellan gum (Kelco gel CG LA, Azelis, UK) in deionized
water. Gellan powder was added to deionized water at ambient
temperature in the correct ratio to result in a 1% (w/v) solution. The sol
was heated to 70 °C under agitation, on a hotplate equipped with a
magnetic stirrer, until all the polymer had dissolved. Once dissolved, gellan
sol was added to the cup of a rotational rheometer (AR-G2, TA Instruments,
UK) equipped with cup and vane geometry (cup: 35 mm diameter, vane:
28mm diameter). The system was then cooled to 40 °C. hrDecorin
(Galacorin™; Catalent, USA) in phosphate-buffered saline (PBS) (4.76mg/
ml) and aqueous sodium chloride (0.2 M) was then added to result in ﬁnal
concentrations of 0.9% (w/v) gellan, 0.24mg/ml hrDecorin and 10mM
NaCl. Following this, the mixture was cooled at a rate of 1 °C/min under
shear (450/s) to a ﬁnal temperature of 20 °C. The sample was then removed
and stored at 4 °C until further use. In the case of ﬂuid gels without
hrDecorin, ratios were adjusted so that the ﬁnal eye drop had a
composition of 0.9% (w/v) gellan, 10 mM NaCl.
Material characterization of the ﬂuid gel eye drops
Microscopy: For transmission microscopy samples were ﬁrst diluted
using polyethylene glycol 400 (PEG400) at a ratio of 1:4 (eye drop to
PEG400). Following this, samples were analyzed using an Olympus FV3000.
Images were processed using ImageJ (http://imagej.nih.gov/ij/; provided in
the public domain by the National Institutes of Health, Bethesda, MD, USA).
For scanning electron microscopy samples were ﬁrst prepared for
lyophilizing by diluting gellan in deionized water in the same manner as
for transmission microscopy to a ratio of 1:9. Samples were then rapidly
frozen using liquid nitrogen and placed in a freeze drier overnight to leave
a powder. Dried sample was then attached to a carbon stub and analyzed
using a SEM.
Rheology: Viscosity proﬁles were obtained using an AR-G2 (TA
Instruments, UK) rheometer equipped with sandblasted parallel plates
(40mm, 1mm gap height) at 20 °C. An equilibrium of 2min was used to
ensure constant test temperature. Following this, time dependent ramps
up and down were applied ranging from 0.1 to 600 /s (3 min sweep times).
Recovery proﬁles were obtained using the same apparatus, under single
Fig. 6 Mechanisms of corneal ﬁbrosis and the effects of hrDecorin ﬂuid gel. If corneal wound-healing fails, high concentrations of TGFβ result
in the continued activation of myoﬁbroblasts within the stroma leading to excessive ECM deposition, disorganized collagen, and
inﬂammation resulting in corneal ﬁbrosis. At this point, although endogenous decorin is present, it is unable to maintain corneal homeostasis.
This may be due to insufﬁcient concentrations to inhibit TGFβ hyperactivity or because the endogenous decorin is not freely available and
bound within the ECM. Providing a sustained release of exogenous hrDecorin from the ﬂuid gel helps to increase decorin levels and reduce
TGFβ hyperactivity, thus providing a permissive environment for wound healing, corneal remodeling, and restoration of corneal integrity
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frequency. The sample underwent rejuvenation by shearing at 600/s for
10 s. Following this, storage and loss (G’, G”, respectively) were monitored
at 1 Hz, 0.5% strain. The crossover point was used as the point at which the
sample started to act like a viscoelastic solid.
hrDecorin release from the ﬂuid gel
Levels of hrDecorin release from the gel were determined cumulatively, by
placing 1ml of the ﬂuid gel containing hrDecorin in a six-well plate. Then
2ml of Dulbecco's modiﬁcation of Eagle medium was placed over the
sample and the plates were incubated at 37 °C. At each time point the
media was removed for measurement of hrDecorin and replaced with
fresh media. Decorin release was quantiﬁed using an enzyme-linked
immunosorbent assay (ELISA) speciﬁc for human Decorin (R&D systems,
Minneapolis, USA) in accordance with the manufacturer’s protocol.
Collagen ﬁbrillogenesis. For the dose–response curves, 75 μl of PBS was
added to each well of a 96-well plate kept on ice. Varying hrDecorin doses
were prepared by adding 400 μg/ml of hrDecorin to the ﬁrst well and
subsequently serial diluting (two-fold dilution) across the plate. Following
dilution, a further 150 μl of PBS buffer was added to each well. Then, 75 μl
of collagen type I (rat tail; Corning, UK) (800 μg/ml) was added to each well
and incubated for 2 h at 37 °C. Subsequent absorbance readings were
taken using a 405 nm plate reader. Each assay consisted of duplicate blank
controls, and triplicate standard dilutions followed by triplicate sample
dilutions. Kinetics of ﬁbril formation were determined using a similar setup
as the dose–response, without serial dilution; incubating the samples
within the plate reader, and taking data points every 2min.
P. keratitis model and in vivo stereomicroscopy
The treatment administration regimes for the in vivo Pseudomonas model
are shown in Fig. 7. Groups of naive intact and infected corneas taken at
day 2 were also included in the experimental plan. The sample size of n= 6
for each control or treatment group was based on the resource equation49
as the effect size was unknown. Mice were randomly assigned to each
treatment and control group before they were infected with Pseudomonas.
Each treatment procedure and the sample sizes are described in further
detail below. For the in vivo studies, analyses were performed by
investigators masked to the experimental groups.
In vivo murine model of P. keratitis
P. aeruginosa PAO1 strain was cultured in high salt Luria Bertani (10 g of
tryptone, 5 g of yeast extract, and 11.7 g of NaCl per L, supplemented with
10mM MgCl2 and 0.5 mM CaCl2) at 37 °C for 18 h. Sub-cultures were
derived at an optic density (OD) of 0.2 (OD 650 nm approx. 1 × 108 CFU/
ml). P. aeruginosa were washed (3×) in PBS, centrifuged at 300 rpm for
5min and re-suspended in PBS at a density of 1 × 105 CFU/2.5 µl. C57BL/6
mice (Jackson Laboratory, CA, USA) were housed in pathogen-free
conditions, given free access to food and water and were maintained
according to the ARRIVE guidelines, the ARVO statement for the Use of
Animals in Ophthalmic and Vision Research and also adhered to guidelines
set out by the University of California, Irvine. For inoculation, mice were
anaesthetized and one corneal epithelium was abraded with 3 × 1mm
parallel scratches using a 26 G needle and inoculated with 2.5 µl P.
aeruginosa (1 × 105 CFU) (strain PAO1)64,65. Mice remained sedated for 2 h
post inoculation to permit penetration of the infection into the eye, and
placed in recovery. After 24 h, conscious mice were treated with 5 µl of
gentamicin (1.5%, QEHB Pharmacy, Birmingham, UK) every 2 h for a 12-
hour period, to sterilize the infection. After a further 12 h, mice were
administered eye drops (5 µl of each compound) every 4 h between 8 am
and 8 pm for a further 13 days depending on their treatment group: (1)
Gentamicin+ Prednisolone (0.5%, QEHB Pharmacy), (2) Gentamicin+
Prednisolone+ ﬂuid gel, or (3) Gentamicin+ Prednisolone+ ﬂuid gel with
hrDecorin. Mice were examined for corneal opaciﬁcation, ulceration, and
perforation. En-face 24-bit color photographs of the cornea were captured
with a SPOT RTKE camera (Diagnostic Instruments) connected to a Leica
MZF III stereo Microscope. Mice were killed by cervical dislocation under
anesthetic at 16 days and eyes enucleated and placed in 4%
paraformaldehyde (PFA) in PBS for processing for immunohistochemistry.
Opacity quantiﬁcation
Two masked independent clinical ophthalmologists analyzed all photo-
graphs in the same randomized order (the order was provided by an
independent statistician). The area of opaciﬁcation was delineated and
measured in mm2 ± SEM using ImageJ. Deﬁnitions of corneal opaciﬁcation,
adequate, and inadequate images were agreed upon prior to commence-
ment of image analysis by the observers. The randomized order dictated
that there should be no time-trend in the measured areas. The limits of
agreement between observers were assessed using the Bland–Altman
method [62] on 99 paired opacity measurements. Differences in
measurement were approximately normally distributed. The Bland–Altman
analysis revealed that one assessor was likely to assess sizes to be slightly
smaller than the other but the mean difference was not statistically
different from zero (two-sided p value= 0.29). A small number of replicates
of measurements within assessor were conducted but not enough to
formally test the limits of agreement within observer.
Tissue processing and immunohistochemistry for re-
epithelialization and ECM
Enucleated eyes for immunochemistry (IHC) were post-ﬁxed by immersion
in 4% in PBS overnight at 4 °C before cryoprotection using increasing
concentrations of sucrose in PBS (10, 20, and 30%; Sigma) for 24 h each at
4 °C. Eyes were then embedded in optimal cutting temperature embed-
ding medium (Thermo Shandon, Runcorn, UK) in peel-away mold
containers (Agar Scientiﬁc, Essex, UK) and later sectioned in the
parasagittal plane at − 22 °C using a cryostat microtome (Bright,
Huntingdon, UK) at a thickness of 15 μm, and placed onto Superfrost
slides (Fisher Scientiﬁc, USA). Central sections (in the optic nerve plane)
were used for all IHC studies and stored at − 80 °C. Frozen sections were
left to thaw for 30min before 3 × 5min washings in PBS followed by a
20min permeabilization with 0.1% Triton X-100 (Sigma). Non-speciﬁc
antibody binding sites in tissue sections were blocked for 30min using
0.5% bovine serum albumin (BSA), 0.3% Tween-20 (all from Sigma), and
15% normal goat serum (Vector Laboratories, Peterborough, UK) in PBS
before incubating overnight in 4 °C in primary antibody (αSMA, Laminin
and ﬁbronectin; 1:200; all from Sigma) again followed by washing 3 ×
5min, and incubating for 1 h at room temperature with a secondary
antibody (Goat anti-mouse Alexa Fluor 488 1:500, Goat anti-mouse Alexa
Fluor 594 1:500, Molecular Probes, Paisley, UK). Sections were then washed
for 3 × 5min and mounted in Vectorshield mounting medium containing
DAPI (Vector Laboratories). Control tissue sections incubated with
secondary antibody alone were all negatively stained.
Immunohistochemical imaging and quantiﬁcation
After IHC, sections were imaged on a Zeiss Axioscanner ﬂuorescent
microscope (Axio Scan.Z1, Carl Zeiss Ltd.) at × 20 using the same exposure
times for each antibody. IHC staining was quantiﬁed by measuring pixel
intensity according to the methods previously described.61 In brief, the
region of interest used for quantitation of ECM IR was deﬁned by a region
of interest which was same prescribed size for all eyes/treatments within
the stroma. Each stroma had a total of 30 individual intensity measure-
ments (regions of interest) taken to cover the whole area. ECM deposition
Fig. 7 In vivo experimental design. Experimental design for the
in vivo Pseudomonas keratitis study in which the ﬂuid gel eye drops
with and without hrDecorin were compared with Gentamicin and
Prednisolone eye drops alone
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was quantiﬁed within these deﬁned regions of interests and the
percentage of IR pixels above a standardized background threshold from
intact corneas was calculated using ImageJ. For each antibody, the
threshold level of brightness in the area of the stroma was set using intact
untreated corneas to deﬁne the reference level for test group analysis.
Images were assigned randomized ﬁle names to ensure masking of
treatment groups for the assessor.
Statistical analysis
All statistical analyses were performed using SPSS 20 (IBM, Chicago, IL,
USA). Normal distribution tests were carried out to determine the most
appropriate statistical analysis to compare treatments. Statistical signiﬁ-
cance was determined at P < 0.05. For opacity measurements, corneal
width, epithelial thickness, αSMA, ﬁbronectin, and laminin data were
analyzed using analysis of variance with Tukey post hoc tests. For 4′,6-
diamidino-2-phenylindole measurements of epithelial cell layer numbers,
as the data were not normally distributed, a Kruskal–Wallis test was used.
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